189 related articles for article (PubMed ID: 1704976)
1. Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs.
Grover GJ; Sleph PG; Dzwonczyk S
J Cardiovasc Pharmacol; 1990 Dec; 16(6):853-64. PubMed ID: 1704976
[TBL] [Abstract][Full Text] [Related]
2. Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate.
McCullough JR; Normandin DE; Conder ML; Sleph PG; Dzwonczyk S; Grover GJ
Circ Res; 1991 Oct; 69(4):949-58. PubMed ID: 1934346
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
Grover GJ; McCullough JR; D'Alonzo AJ; Sargent CA; Atwal KS
J Cardiovasc Pharmacol; 1995 Jan; 25(1):40-50. PubMed ID: 7723352
[TBL] [Abstract][Full Text] [Related]
4. The KATP blocker sodium 5-hydroxydecanoate does not abolish preconditioning in isolated rat hearts.
Grover GJ; Murray HN; Baird AJ; Dzwonczyk S
Eur J Pharmacol; 1995 Apr; 277(2-3):271-4. PubMed ID: 7493619
[TBL] [Abstract][Full Text] [Related]
5. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
[TBL] [Abstract][Full Text] [Related]
6. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
[TBL] [Abstract][Full Text] [Related]
7. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
[TBL] [Abstract][Full Text] [Related]
8. Nicorandil improves postischemic contractile function independently of direct myocardial effects.
Grover GJ; Sleph PG; Parham CS
J Cardiovasc Pharmacol; 1990 May; 15(5):698-705. PubMed ID: 1692928
[TBL] [Abstract][Full Text] [Related]
9. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs.
Grover GJ; Dzwonczyk S; Parham CS; Sleph PG
Cardiovasc Drugs Ther; 1990 Apr; 4(2):465-74. PubMed ID: 2285630
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
[TBL] [Abstract][Full Text] [Related]
11. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS
Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
[TBL] [Abstract][Full Text] [Related]
12. Reduction of ischemic damage in isolated rat hearts by the potassium channel opener, RP 52891.
Grover GJ; Dzwonczyk S; Sleph PG
Eur J Pharmacol; 1990 Nov; 191(1):11-8. PubMed ID: 2128745
[TBL] [Abstract][Full Text] [Related]
13. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
[TBL] [Abstract][Full Text] [Related]
14. Comparative cardioprotective effects of cromakalim and diltiazem in ischemic hypertrophied rat hearts.
Grover GJ; Dzwonczyk S; Monticello TM
Am J Physiol; 1996 Jan; 270(1 Pt 2):H174-82. PubMed ID: 8769749
[TBL] [Abstract][Full Text] [Related]
15. Glyburide-reversible cardioprotective effects of calcium-independent phospholipase A2 inhibition in ischemic rat hearts.
Sargent CA; Wilde MW; Dzwonczyk S; Tuttle JG; Murray HN; Atwal K; Grover GJ
Cardiovasc Res; 1996 Feb; 31(2):270-7. PubMed ID: 8730404
[TBL] [Abstract][Full Text] [Related]
16. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Tosaki A; Szerdahelyi P; Engelman RM; Das DK
J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
[TBL] [Abstract][Full Text] [Related]
17. Glyburide-reversible cardioprotective effects of BMS-180448: functional and energetic considerations.
Grover GJ; Sleph PG; Dzwonczyk S; Malone HJ; Behling RW
J Cardiovasc Pharmacol; 1997 Jan; 29(1):28-38. PubMed ID: 9007667
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR
J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
[TBL] [Abstract][Full Text] [Related]
19. Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate.
Auchampach JA; Grover GJ; Gross GJ
Cardiovasc Res; 1992 Nov; 26(11):1054-62. PubMed ID: 1291082
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective effects of (2S,3R,4S)-N'-benzyl-N"-cyano-N-(3,4-dihydro-2-dimethoxymethyl-3-hydroxy-2-methyl-6-nitro-2H-benzopyran-4-yl)-guanidine (KR-31372) in rats and dogs.
Lee BH; Seo HW; Yoo SE
Pharmacology; 2004 Feb; 70(2):74-82. PubMed ID: 14685010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
